StoneX Group’s Aprea Therapeutics APRE Stock Holding History

StoneX Group’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-626	Closed	-$8.14K	–	591
2022 Q3	$8.14K	Sell	626 -109	-15%	-$1.93K	﹤0.01%	304
2022 Q2	$11K	Buy	+735	New	+$16.9K	﹤0.01%	458

Other funds holding APRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

StoneX Group's APRE Position: Q4 2022 in Review

StoneX Group sold out of Aprea Therapeutics (APRE) in Q4 2022, closing a stake of 626 shares — an estimated $8.14K sold.

StoneX Group first reported a position in APRE in Q2 2022 and held it in 2 quarters. The position peaked at $11K in Q2 2022. 24 funds tracked by Wall St. Rank hold APRE as of Q4 2022.

StoneX Group reported no remaining Aprea Therapeutics position as of Q4 2022 after selling out during the quarter.
StoneX Group sold 626 Aprea Therapeutics shares in Q4 2022, an estimated $8.14K.
StoneX Group first reported a position in Aprea Therapeutics in Q2 2022 and held it in 2 quarters.
StoneX Group's Aprea Therapeutics position peaked at $11K in Q2 2022.
24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.